Ultraview diaminobenzidine kit

Manufactured by Roche

Sourced in United States

The UltraView diaminobenzidine kit is a laboratory reagent used in immunohistochemistry procedures. It provides a visualization system for the detection of target proteins or antigens in tissue samples. The kit contains the necessary components to enable a chromogenic detection reaction that results in a brown staining at the sites of the target molecules.

Automatically generated - may contain errors

Lab products found in correlation

Benchmark ultra, by Roche (2 mentions)

Close spelling variants of this product

XT UltraView diaminobenzidine kit UltraView Universal DAB (diaminobenzidine tetrahydrochloride) Detection Kit UltraView Universal diaminobenzidine detection kit UltraView Universal diaminobenzidine (DAB) detection kit

2 protocols using ultraview diaminobenzidine kit

Immunohistochemical Analysis of PD-L1 and CD8 in FFPE Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

All immunohistochemical stainings were done on 5 μm whole standard tissue sections of formaldehyde-fixed paraffin-embedded tissue (FFPE) tumor samples (see Fig. 1). For the detection of PD-L1 prediluted PD-L1 rabbit monoclonal antibody (SP263; Ventana Medical Systems, Oro Valley, Arizona) was used as the primary antibody. Immunohistochemical staining for CD8 was carried out with an anti- CD8α mouse monoclonal antibody (C8/144B, Cell Marque, Rocklin, California, dilution 1:50) as the primary antibody. Both stainings were performed on a Ventana Benchmark Ultra autostainer using the UltraView diaminobenzidine kit (Ventana Medical Systems, Oro Valley, AZ).
Fig. 1

PD-L1 expression on tumor cells and CD8 expression on tumor infiltrating lymphocytes. Representative images under a microscope with a 10x enlargement of adenocarcinomas with positive (a, 80%) and negative (b, 0%) PD-L1 staining on tumor cells and adenocarcinomas with positive (c, 70%) and negative (d, 2%) CD8 staining on tumor infiltrating lymphocytes. The arrows indicate positive (a,c) or negative (b,d) staining

Gennen K., Käsmann L., Taugner J., Eze C., Karin M., Roengvoraphoj O., Neumann J., Tufman A., Orth M., Reu S., Belka C, & Manapov F. (2020). Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology (London, England), 15, 5.

+ Open protocol

+ Expand

Immunohistochemical Analysis of PD-L1 and CD8 in FFPE Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed using formaldehyde-fixed paraffin-embedded (FFPE) tissue specimens obtained on the first diagnostic biopsy of 84 patients. Immunohistochemical staining was performed with 5-µm entire standard tissue sections of FFPE tumor samples. To detect PDL1, a pre-diluted PDL1 rabbit monoclonal antibody (SP263; Ventana Medical Systems, Oro Valley, Arizona, USA) was used as the primary antibody, with staining performed on a Ventana Benchmark Ultra autostainer using an UltraView diaminobenzidine kit (Ventana Medical Systems, Oro Valley, AZ, USA). Immunohistochemical staining for CD8 expression on T cells was performed using an anti-CD8 mouse monoclonal antibody (clone 144 B, diluted 1:100; Abcam, Cambridge, UK) as the primary antibody, with staining performed using the BondMax Leica autostainer.

Kim Y.H., Choi Y.D., Ahn S.J., Kim Y.C., Oh I.J., Nam T.K., Jeong J.U, & Song J.Y. (2024). Blood Lymphocytes as a Prognostic Factor for Stage III Non-Small Cell Lung Cancer with Concurrent Chemoradiation. Chonnam Medical Journal, 60(1), 40-50.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!